North Macedonia cannabis disruptor with EU-GMP compliant facility for purchase!

Fully licensed, ~2,500 m² EU GMP compliant pharmaceutical facility for the manufacturing, R&D, processing, packaging and import/ export of medicinal cannabis globally includes flower, extracts and final product

25 acres of commercial land owned and 5 acres are licensed for production (greenhouse or indoor) and outdoor cultivation

Facility is capable of tolling 1000 KG’s of dried flower per month (i.e. GACP to GMP conversion), extraction capacity of 130 lts per month (EU-GMP), internal cultivation of 100kg per month (EU GMP), outdoor cultivation minimum potential of 4,000KGs per annum and further capabilities for packaging, white labeling, finished product, and stability chambers

Current facility has the capacity for over €20m of annual production

Urban plan and taxes paid for an additional 13,000sqm production space leading to a minimum of €100m p.a. of additional capacity

World-class, EU GMP trained team with domain and industry leadership spanning medical, pharmaceuticals, technology and cannabinoids

Have established a number of key relationships with clinics, distributors, university partners and other commercial partners

Commercial partnerships UK / Poland / Germany / Australia

Built and growing an €18m pipe lineDiversified supply agreements are in place and multiple LOIs/contracts are underway

Exclusive contract for cannabis cultivation and supply to a UK cannabinoid FDA Botanical Pathway Drug Development company

Company has been awarded two local government grant contracts, R&D tax rebates., and local bank lending with 10% corporation tax

26% rebate on CAPEX

Strategically positioned as a key gateway for importing and exporting cannabis and cannabis products to and from Europe, poised to emerge as a prominent force in pioneering cannabinoid-based medication and technology within the European and global cannabis industries

Seeking outright divestiture of the wholly owned land and building, licences, and going-concern business in North Macedonia. There is an option to acquire additional cannabinoid/IP assets from the UK parent company.